CClinicalTrials.gg
CompletedNCT01522495Updated Mar 11, 2020

Pilot Study to Determine Percent Tissue Perfusion and Cellular Viability Using SPY Imaging

An interventional study of SPY Imaging, ICG dye (0.2 - 0.5 mg/kg) and SPY Imaging in Peripheral Vascular Disease, sponsored by Georgetown University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-11.

Sponsored by Georgetown University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Little is known about chronic wound microenvironments, especially in peripheral vascular disease (PVD) and diabetic patients. At the demarcation line, the percentage of viable cells and tissue is unclear. A means to determine cell viability, particularly discerning an apoptotic or necrotic cell pathway would indicate where the line of demarcation should be drawn. The information generated would better predict clinical outcome using SPY Imaging. Cellular studies are needed to successfully confirm a clear line of demarcation to eliminate surgeon subjectivity.

Read the detailed description

Peripheral arterial disease (PAD), like other more central macrovascular diseases, is common in diabetes. PAD can lead to critical limb ischemia, either alone or when combined with an injury like a foot ulcer. The diabetic foot ulceration requires adequate circulation to heal; if the circulation is impaired such that the tissue oxygen demand exceeds supply, critical limb ischemia ensues, placing the limb at risk.

Most often, patients with critical limb ischemia, undergo multiple debridements in the operating room as well as vascular procedures, prior to reaching a viable level of amputation. This increases the patients' co-morbidities from repetitive exposure to anesthesia. Each debridement may be removing viable tissue and decreasing the length of the eventual amputation. Additionally, intraoperatively, the viability of the skin edges is a subjective assessment based on the surgeon's experience. That judgement can be inaccurate in 10-20% of cases and lad to reoperation. With the use of the SPY imaging system, a better assessment of not only macrovascularity, but also microvascularity of the tissues is able to be evaluated objectively. This helps identify the tissues that are underperfused.

The investigators are unaware of any literature evaluating the use of SPY imaging in the lower extremities intraoperatively during amputations or debridements. There are many studies published for the use of this technology during ophthalmic procedures , cerebral aneurismal repair, cardiac surgery and breast reconstruction. In cardiac surgery, the use of ICG based imaging has proven to be helpful in assessing the quality of bypass grafts and eliminating the need for radiography or catheter insertion (Reuthebuch et al., 2004). In ophthalmic procedures, ICG angiography has been fundamental in identifying many microvascular pathologies (Slakter, Yannuzzi, Guyer, Sorenson, \& Orlock, 1995). Furthermore, neurosurgeons have found that the use of ICG angiography is far more superior than DS angiography in identifying small vessels . As it has already been proven to be a good adjunct intraoperatively to visualize microvasculature, the investigators would like to apply this to the lower extremities. Identifying underperfused tissues intraoperatively can help the surgeon objectively decide an appropriate level of amputation/debridement to effectively minimize the number of revisional surgeries. Also, there are no studies that comprehensively evaluate and compare the effectiveness of other modalities that also attempt to assess vascularity with the SPY imaging system. The information gained could be pivotal and help to gain more insight in patients with difficult to heal wounds, especially in the presence of PVD.

02

Conditions studied

03

In context

Vascular Diseases

1,027 studies on the registry are indexed under Vascular Diseases; 167 are open to participants now.

This study's enrollment of 31 is below the median of 78 across 639 interventional studies indexed under Vascular Diseases.

Browse Vascular Diseases studies →

Lead sponsor

Georgetown University is the lead sponsor of 286 studies on the registry; 42 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 20 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subject is at least 18 years or older.
  • Subject has PVD demonstrated by angiogram.
  • Subject is undergoing the first amputation/debridement after vascular intervention, if intervention is/was warranted.
  • Subject has had a vascular consult and/or intervention.
  • Subject must sign an IRB approved informed consent.
  • Subject is willing and able to complete required follow up.

Exclusion criteria

Exclusion Criteria:

  • Subject has no evidence of PVD
  • Subject's wound presents with a malignancy in the wound bed.
  • Subject has liver disease (Previously diagnosed with liver disease or elevated AST, ALT, Alk Phos, or Bilirubin labs within 30 days of procedure).
  • Subject has a disorder or situation that the investigator believes will interfere with study compliance.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    SPY Imaging

    SPY Imaging Prior to Amputation or Debridements (50 participants)

    Device: SPY Imaging, ICG dye (0.2 - 0.5 mg/kg) · Device: SPY Imaging

  • No intervention
    No SPY Imaging

    Amputation or Debridements as Standard of Care (50 participants)

  • Experimental
    Validation Against Angiogram

    Patients who are scheduled to undergo an angiogram will also receive ICG angiography (SPY). This will occur at specific time points: 1.) before the angiogram/intervention is performed 2.) immediately after the angiogram/intervention is performed 3.) 5-7 days after angiogram/intervention 4.) 21-30 days after angiogram/intervention. (30 participants)

    Device: SPY Imaging, ICG dye (0.2 - 0.5 mg/kg) · Device: SPY Imaging

  • Experimental
    Establishing Normal Values

    To establish baseline lower extremity perfusion in non-PVD patients. Patients requiring an angiogram for other vascular processes unrelated to the lower extremity will be recruited into this study. ICG angiography (SPY) of the lower extremity will be performed at the time of the angiogram. (30 Participants)

    Device: SPY Imaging, ICG dye (0.2 - 0.5 mg/kg) · Device: SPY Imaging

Interventions

  • DeviceSPY Imaging, ICG dye (0.2 - 0.5 mg/kg)

    Intravenous(1X) in conjunction with SPY Imaging (1 arm)

    Also known as: Indocyanine Green, IC-GREEN

  • DeviceSPY Imaging

    SPY Imaging to assess tissue perfusion

06

What researchers measure

Primary outcomes

  1. Determination of percent cellular viability

    Determine percent cellular viability (vs. apoptotic/dead) of cells at demarcation line

    Time frame: 6 weeks

  2. Rate of infection, dehiscence and re-amputation

    Rate of infection, dehiscence and re-amputation in patients undergoing SPY imaging

    Time frame: 20 weeks

  3. Number of debridements, revisional surgeries and days of stay in hospital

    The endpoint for evaluation will be the number of revisional surgeries and number of days of stay in hospital within 20 weeks of the first procedure.

    Time frame: 20 weeks

07

Study locations

1 site
  • Georgetown University Medical Center; Center for Wound Healing
    Washington, District of Columbia 20007, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01522495
Lead sponsor
Georgetown University
Responsible party
Christopher Attinger, M.D. (Chief of the Division of The Center for Wound Healing, Georgetown University) — Principal investigator
First posted
Jan 31, 2012
Start date
Apr 2013
Primary completion
Dec 2019
Completion
Dec 2019
Last update
Mar 11, 2020

Study contacts

Christopher E Attinger, MD
principal investigator · Georgetown University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion